0001209191-22-055828.txt : 20221104
0001209191-22-055828.hdr.sgml : 20221104
20221104172345
ACCESSION NUMBER: 0001209191-22-055828
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221102
FILED AS OF DATE: 20221104
DATE AS OF CHANGE: 20221104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schor Chen
CENTRAL INDEX KEY: 0001340875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 221363134
MAIL ADDRESS:
STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC.
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-02
0
0001720580
Adicet Bio, Inc.
ACET
0001340875
Schor Chen
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
1
1
0
0
President & CEO
Common Stock
2022-11-02
4
S
0
500
18.00
D
138237
I
See Footnote
Common Stock
2022-11-03
4
S
0
24813
18.0437
D
113424
I
See Footnote
Common Stock
101424
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $18.00 to $18.25, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission staff upon request.
/s/ Nick Harvey, Attorney-in-Fact
2022-11-04